Royalty Pharma (RPRX) – Analysts’ Weekly Ratings Updates

Royalty Pharma (NASDAQ: RPRX) has recently received a number of price target changes and ratings updates:

• 1/30/2026 – Royalty Pharma was upgraded by analysts at UBS Group AG from a “neutral” rating to a “buy” rating. They now have a $49.00 price target on the stock.
• 1/27/2026 – Royalty Pharma had its price target raised by analysts at Citigroup Inc. from $48.00 to $50.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Royalty Pharma had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 1/17/2026 – Royalty Pharma was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/11/2025 – Royalty Pharma was given a new $45.00 price target on by analysts at Leerink Partners.
• 12/11/2025 – Royalty Pharma had its “buy” rating reaffirmed by analysts at TD Cowen.
• 12/11/2025 – Royalty Pharma had its price target raised by analysts at TD Cowen from $42.00 to $45.00. They now have a “buy” rating on the stock.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be issued a $0.235 dividend. The ex-dividend date of this dividend is Friday, February 20th. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 annualized dividend and a yield of 2.3%. Royalty Pharma’s dividend payout ratio is 71.21%.

Insiders Place Their Bets

In related news, EVP George W. Lloyd sold 30,654 shares of the stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $38.50, for a total value of $1,180,179.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Marshall Urist sold 20,000 shares of the stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $40.26, for a total transaction of $805,200.00. Following the transaction, the executive vice president directly owned 20,000 shares of the company’s stock, valued at $805,200. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 1,045,675 shares of company stock worth $40,833,596. Corporate insiders own 18.90% of the company’s stock.

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.